Greenland Mines (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year.
Questions around this news
What does the Canadian patent cover?
The patent covers use of the secreted Klotho RNA splice variant, known as s-KL, in genetic therapies. The release says its 42 claims address synthesis and delivery methods, as well as potential use across neurological disorders including Alzheimer’s disease, Parkinson’s disease, ALS and multiple sclerosis. The technology is exclusively licensed by Greenland Mines.
What are the next development steps for KLTO-101 and KLTO-202?
The company said process development and manufacturing for KLTO-101 are scheduled to start in August 2026. KLTO-202 has moved into GMP manufacturing, with the company preparing for regulatory interactions later in the year. The release does not provide further details about the planned regulatory discussions or development timelines beyond those statements.
What does GMP manufacturing mean?
GMP stands for Good Manufacturing Practice. It refers to quality requirements for making medicines and other regulated products, including controls over facilities, equipment, production processes, records and testing. The goal is to ensure products are consistently made and controlled according to applicable quality standards; the precise requirements depend on the product and regulatory jurisdiction.
What is a secreted Klotho RNA splice variant?
RNA splicing is a process in which cells edit an initial RNA copy of a gene, combining selected segments into a mature message. Different splice patterns can produce distinct forms of a protein. A secreted Klotho variant is a form associated with release outside the cell, rather than remaining anchored to the cell membrane.
To view the full press release, visit: https://ibn.fm/x2pHA
About Greenland Mines
Greenland Mines Ltd. is a Nasdaq-listed company with two operating divisions: (1) Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and (2) Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
At a glance
- Company
- Greenland Mines Ltd.
- Ticker
- NASDAQ: GRML
- Announcement
- Regulatory
- Location
- Canada
Key figures
- Patent claims
- 42
- KLTO-101 process development and manufacturing start
- August 2026
Products and programs
SEC filings
Earlier from Greenland Mines
- Greenland Mines (NASDAQ: GRML) Advances World-Class Palladium Deposit with Major Resource Upgrade
- Greenland Mines (NASDAQ: GRML) Adopts One-Year Stockholder Rights Plan
- Greenland Mines (NASDAQ: GRML) Ties Together Rare Earths, Advanced Materials in Single Share Exchange
- Greenland Mines (NASDAQ: GRML) Reports 31% Increase in Indicated Palladium Equivalent Resource at Skaergaard Project
- Greenland Mines (NASDAQ: GRML) Secures Australian Patent for Klotho Gene Therapy Platform
